SGMO
Sangamo Therapeutics, Inc.$0.18+0.00 (—)Prev Close$0.14·MCap$87.0M·P/E—·Vol—·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
22
$433.3K
◆
Net Activity
Net Seller
$433.3K
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Sangamo Therapeutics, Inc. (SGMO) has been exclusively selling, with 0 insider purchases totaling $0.00 and 22 insider sales totaling $433.3K. The most recent insider transaction was by Davis Gregory D (officer: Head of Research & Technology), who sold $17.7K worth of shares on Apr 23, 2026. Sangamo Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $87.0M.
SGMO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Davis Gregory D | officer: Head of Research & Technology | Sell | 69,827 | $0.25 | $17.7K | 115,284-38% |
| Apr 23, 2026 | Dubois-Stringfellow Nathalie | officer: SVP-CHIEF DEVELOPMENT OFFICER | Sell | 345,942 | $0.26 | $89.2K | 332,769-51% |
| Jan 22, 2026 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 36,676 | $0.40 | $14.6K | 0 |
| Jan 22, 2026 | Jain Nikunj | Principal Accounting Officer | Sell | 7,721 | $0.40 | $3.1K | 0 |
| Jan 22, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 102,950 | $0.40 | $41.0K | 0 |
| Nov 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.42 | $301.20 | 0 |
| Nov 24, 2025 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 2,544 | $0.42 | $1.1K | 0 |
| Nov 24, 2025 | Jain Nikunj | Principal Accounting Officer | Sell | 578 | $0.42 | $240.79 | 0 |
| Nov 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.42 | $3.1K | 0 |
| Nov 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 2,035 | $0.42 | $847.78 | 0 |
| Oct 22, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 43,741 | $0.66 | $28.9K | 0 |
| Oct 22, 2025 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 45,225 | $0.66 | $29.8K | 0 |
| Oct 22, 2025 | Jain Nikunj | Principal Accounting Officer | Sell | 6,708 | $0.66 | $4.4K | 0 |
| Oct 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.66 | $83.8K | 0 |
| Oct 22, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 44,122 | $0.66 | $29.1K | 0 |
| Aug 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.59 | $423.89 | 0 |
| Aug 24, 2025 | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | Sell | 1,792 | $0.59 | $1.1K | 0 |
| Aug 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.59 | $4.4K | 0 |
| Aug 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 1,434 | $0.59 | $840.75 | 0 |
| Jul 22, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 6,708 | $0.48 | $3.2K | 0 |
| Jul 22, 2025 | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | Sell | 31,866 | $0.48 | $15.3K | 0 |
| Jul 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.48 | $60.9K | 0 |
| May 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.47 | $342.20 | 0 |
| May 24, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 1,792 | $0.47 | $848.15 | 0 |
| May 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.47 | $3.5K | 0 |
| May 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 1,433 | $0.47 | $678.24 | 0 |
| Apr 22, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 6,708 | $0.78 | $5.2K | 0 |
| Apr 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.78 | $98.6K | 0 |
| Apr 22, 2025 | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Sell | 31,866 | $0.78 | $24.7K | 0 |
| Feb 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 1,212 | $0.98 | $1.2K | 0 |
| Feb 24, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 3,305 | $0.98 | $3.2K | 0 |
| Feb 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 18,151 | $0.97 | $17.7K | 0 |
| Feb 24, 2025 | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Sell | 2,809 | $0.98 | $2.7K | 0 |
| Sep 28, 2023 | BIOGEN INC. | 10% Owner | Sell | 6,000,000 | $0.50 | $3.00M1.6% OS | 17,652,466-25% |
| Aug 31, 2022 | BIOGEN INC. | 10% Owner | Sell | 500,000 | $5.31 | $2.66M | 23,752,466 |
| Jun 6, 2022 | Markels John | Director | Buy | 6,784 | $3.69 | $25.0K | 32,484+26% |
| Jun 3, 2022 | PARKER H STEWART | Director | Buy | 5,000 | $3.60 | $18.0K | 48,700 |
| Dec 30, 2021 | BIOGEN INC. | 10% Owner | Sell | 2,764 | $8.51 | $23.5K | 24,152,466 |
| Dec 28, 2021 | BIOGEN INC. | 10% Owner | Sell | 81,787 | $8.55 | $699.7K | 24,155,830 |
| Dec 10, 2021 | BIOGEN INC. | 10% Owner | Sell | 23,660 | $8.56 | $202.5K | 24,237,016 |
| Dec 9, 2021 | BIOGEN INC. | 10% Owner | Sell | 127,992 | $8.59 | $1.10M | 24,336,492 |
| Dec 3, 2021 | BIOGEN INC. | 10% Owner | Sell | 2,604 | $8.51 | $22.2K | 24,390,544 |
| Nov 30, 2021 | BIOGEN INC. | 10% Owner | Sell | 28,884 | $8.60 | $248.4K | 24,391,272 |
| Mar 25, 2021 | LOEB GARY | EVP, General Counsel & Sec. | Sell | 17,524 | $13.13 | $230.0K | 88,781 |
SGMO Insider Buying Activity
The following table shows recent insider purchases of Sangamo Therapeutics, Inc. (SGMO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 6, 2022 | Markels John | Director | Buy | 6,784 | $3.69 | $25.0K | 32,484+26% |
| Jun 3, 2022 | PARKER H STEWART | Director | Buy | 5,000 | $3.60 | $18.0K | 48,700 |
SGMO Insider Selling Activity
The following table shows recent insider sales of Sangamo Therapeutics, Inc. (SGMO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Davis Gregory D | officer: Head of Research & Technology | Sell | 69,827 | $0.25 | $17.7K | 115,284-38% |
| Apr 23, 2026 | Dubois-Stringfellow Nathalie | officer: SVP-CHIEF DEVELOPMENT OFFICER | Sell | 345,942 | $0.26 | $89.2K | 332,769-51% |
| Jan 22, 2026 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 36,676 | $0.40 | $14.6K | 0 |
| Jan 22, 2026 | Jain Nikunj | Principal Accounting Officer | Sell | 7,721 | $0.40 | $3.1K | 0 |
| Jan 22, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 102,950 | $0.40 | $41.0K | 0 |
| Nov 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.42 | $301.20 | 0 |
| Nov 24, 2025 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 2,544 | $0.42 | $1.1K | 0 |
| Nov 24, 2025 | Jain Nikunj | Principal Accounting Officer | Sell | 578 | $0.42 | $240.79 | 0 |
| Nov 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.42 | $3.1K | 0 |
| Nov 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 2,035 | $0.42 | $847.78 | 0 |
| Oct 22, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 43,741 | $0.66 | $28.9K | 0 |
| Oct 22, 2025 | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | Sell | 45,225 | $0.66 | $29.8K | 0 |
| Oct 22, 2025 | Jain Nikunj | Principal Accounting Officer | Sell | 6,708 | $0.66 | $4.4K | 0 |
| Oct 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.66 | $83.8K | 0 |
| Oct 22, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 44,122 | $0.66 | $29.1K | 0 |
| Aug 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.59 | $423.89 | 0 |
| Aug 24, 2025 | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | Sell | 1,792 | $0.59 | $1.1K | 0 |
| Aug 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.59 | $4.4K | 0 |
| Aug 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 1,434 | $0.59 | $840.75 | 0 |
| Jul 22, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 6,708 | $0.48 | $3.2K | 0 |
| Jul 22, 2025 | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | Sell | 31,866 | $0.48 | $15.3K | 0 |
| Jul 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.48 | $60.9K | 0 |
| May 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 723 | $0.47 | $342.20 | 0 |
| May 24, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 1,792 | $0.47 | $848.15 | 0 |
| May 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 7,488 | $0.47 | $3.5K | 0 |
| May 24, 2025 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | Sell | 1,433 | $0.47 | $678.24 | 0 |
| Apr 22, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 6,708 | $0.78 | $5.2K | 0 |
| Apr 22, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 126,950 | $0.78 | $98.6K | 0 |
| Apr 22, 2025 | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Sell | 31,866 | $0.78 | $24.7K | 0 |
| Feb 24, 2025 | Davis Gregory D | Head of Research & Technology | Sell | 1,212 | $0.98 | $1.2K | 0 |
| Feb 24, 2025 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 3,305 | $0.98 | $3.2K | 0 |
| Feb 24, 2025 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | Sell | 18,151 | $0.97 | $17.7K | 0 |
| Feb 24, 2025 | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Sell | 2,809 | $0.98 | $2.7K | 0 |
| Sep 28, 2023 | BIOGEN INC. | 10% Owner | Sell | 6,000,000 | $0.50 | $3.00M1.6% OS | 17,652,466-25% |
| Aug 31, 2022 | BIOGEN INC. | 10% Owner | Sell | 500,000 | $5.31 | $2.66M | 23,752,466 |
| Dec 30, 2021 | BIOGEN INC. | 10% Owner | Sell | 2,764 | $8.51 | $23.5K | 24,152,466 |
| Dec 28, 2021 | BIOGEN INC. | 10% Owner | Sell | 81,787 | $8.55 | $699.7K | 24,155,830 |
| Dec 10, 2021 | BIOGEN INC. | 10% Owner | Sell | 23,660 | $8.56 | $202.5K | 24,237,016 |
| Dec 9, 2021 | BIOGEN INC. | 10% Owner | Sell | 127,992 | $8.59 | $1.10M | 24,336,492 |
| Dec 3, 2021 | BIOGEN INC. | 10% Owner | Sell | 2,604 | $8.51 | $22.2K | 24,390,544 |
| Nov 30, 2021 | BIOGEN INC. | 10% Owner | Sell | 28,884 | $8.60 | $248.4K | 24,391,272 |
| Mar 25, 2021 | LOEB GARY | EVP, General Counsel & Sec. | Sell | 17,524 | $13.13 | $230.0K | 88,781 |
SGMO Insiders
Similar Stocks to SGMO
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B